Health Affairs February 20, 2024
Christina Bush, Frank McStay, Mark Japinga, Nitzan Arad, Robert S. Saunders

There has been recent policy interest in improving the affordability and access of prescription medications, including efforts to reduce disparities in access for low-income and minority beneficiaries. For example, the Inflation Reduction Act (IRA) is being implemented in response to continued concerns about drugs affordability, with a focus on reducing the price of selected drugs paid for by the Medicare program. States have also implemented a range of policies for reducing the unit price of drugs, such as preferred drug lists and multistate purchasing collaboratives. Legislation is currently being considered by congressional committees focused on pharmacy benefit managers (PBMs) in terms of rebates, certain types of transparency, spread pricing, and fee models.

These drug policies are unlikely to achieve their...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Patient / Consumer, Payment Models, Pharma, Pharma / Biotech, Provider, Value Based
Related Articles:
Podcast: Medicare Shared Savings Program Mints $2B Win for Value-Based Care w/ Frank McStay
AHA, others urge Congress to act on alternative payment models, avoid physician payment cut
Value-Based Care Is a Four Layer Cake — Why Do We Only Focus on The Icing?
Cityblock Health Validates Value-Based Care Arrangement with 11.5% Payer Expense Reduction
Podcast: What Direction Will Alternative Payment Models Head Over the Next Four Years? 11/21/24

Share This Article